Vasculox, Inc seeks to exploit a previously unknown mode of vascular regulation to prevent tissue ischemia as a result of trauma, surgery or vascular disease.
Nitric oxide (NO) is a master regulator of the cardiovascular system. NO governs tissue perfusion, and insufficient NO production or signaling contributes to many vascular diseases including hypertension, atherosclerosis, diabetic vasculopathy and metabolic syndrome.
The founders of Vasculox have discovered a mechanism that limits the dynamic range of NO signaling throughout the vascular system. By selectively blocking this mechanism, the ability of NO to open blood vessels and increase blood flow to tissues is increased thus improving or maintaining tissue viability. This approach will have many applications in treatment of cardiovascular disease and other situations in which NO bioavailability is limited.
